FDA inspection
Dansk Salt A/S: FDA inspection ending Mar 24, 2006
FDA inspection 420497 · Voluntary Action Indicated (VAI) · Mariager
Key facts
| Inspection ID | 420497 |
|---|---|
| Firm | Dansk Salt A/S |
| FEI number | 3005406532 |
| Address | Hadsundvej 17 |
| City | Mariager |
| Fiscal year | 2006 |
| Inspection end date | Mar 24, 2006 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation |
| Product type | Drugs |
At a glance
- None Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data